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David Gómez-Andrés41 , Hanns Lochmüller 27,42,43,44 , Hélène Dollfus45 ,
Sergio Rosenzweig46 , Shruti Marwaha35 , Ana Rath 32 , Kathleen Sullivan47 ,
Cynthia Smith 33 , Joshua D. Milner24 , Dorothée Leroux45 , Cornelius F. Boerkoel34 ,
Amy Klion24 , Melody C. Carter24 , Tudor Groza3,22 , Damian Smedley3,6 , Melissa
A. Haendel3,5,9 , Chris Mungall3,7 and Peter N. Robinson 3,4,48,*

Nucleic Acids Research, 2019, Vol. 47, Database issue D1019

Received September 17, 2018; Revised October 18, 2018; Editorial Decision October 19, 2018; Accepted October 24, 2018

ABSTRACT

INTRODUCTION

The Human Phenotype Ontology (HPO)––a standardized vocabulary of phenotypic abnormalities associated with 7000+ diseases––is used by thousands
of researchers, clinicians, informaticians and electronic health record systems around the world. Its
detailed descriptions of clinical abnormalities and
computable disease definitions have made HPO the
de facto standard for deep phenotyping in the field
of rare disease. The HPO’s interoperability with other
ontologies has enabled it to be used to improve diagnostic accuracy by incorporating model organism
data. It also plays a key role in the popular Exomiser
tool, which identifies potential disease-causing variants from whole-exome or whole-genome sequencing data. Since the HPO was first introduced in 2008,
its users have become both more numerous and
more diverse. To meet these emerging needs, the
project has added new content, language translations, mappings and computational tooling, as well
as integrations with external community data. The
HPO continues to collaborate with clinical adopters
to improve specific areas of the ontology and extend standardized disease descriptions. The newly
redesigned HPO website (www.human-phenotypeontology.org) simplifies browsing terms and exploring clinical features, diseases, and human genes.

A cornerstone of differential diagnostics and translational
research is deep phenotyping: the computational analysis
of detailed, individual clinical abnormalities (1,2). The Human Phenotype Ontology (HPO) provides the most comprehensive resource for computational deep phenotyping
and has become the de facto standard for deep phenotyping in the field of rare disease––whether for computable
disease definitions, description of clinical abnormalities or
to aid genomic diagnostics. A foundational and integrative
component of the Monarch Initiative (3,4), the HPO has
been adopted internationally by numerous organizations,
both academic and commercial; these include the 100,000
Genomes Project, the NIH Undiagnosed Disease Program
and Network (UDP and UDN), the Undiagnosed Diseases
Network International (UDNI), RD-CONNECT, SOLVERD and many others (5–9). The HPO recently achieved
status as an International Rare Disease Research Consortium (IRDiRC) recognized resource and is in use by the
Global Alliance for Genomics and Health (10) and the associated Matchmaker Exchange (3,11). Here we describe integrated HPO resources which we have revised, expanded,
or invented since the previous articles in this series (12,13).
Previously, we reported on a range of algorithms that
had been developed by our group and others to support
phenotype-driven genomic diagnostics (12). Since then, the
HPO has been applied to an increasing range of use cases.
Usage of HPO is now commonplace for the analysis of
clinical whole-exome and genome sequencing (WES/WGS)
data (14–25) as well as for data integration in translational research and bioinformatics (16,26–39). A phenotype
risk score based on a mapping of electronic health-record
(EHR)-derived billing codes to HPO terms allowed high-

Downloaded from https://academic.oup.com/nar/article-abstract/47/D1/D1018/5198478 by Jackson Laboratory user on 15 January 2019

USA, 25 Rat Genome Database, Department of Biomedical Engineering, Medical College of Wisconsin & Marquette
University, 8701 Watertown Plank Road Milwaukee, WI 53226, USA, 26 Bioscientia GmbH, Ingelheim, Germany,
27
CNAG-CRG, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Baldiri
Reixac 4, Barcelona 08028, Spain, 28 Universitat Pompeu Fabra (UPF), Barcelona, Spain, 29 University of Manchester
& Manchester Royal Eye Hospital, Manchester, UK, 30 ICF, Rockville, MD, USA, 31 National Center for Advancing
Translational Sciences, Office of Rare Diseases Research, National Institutes of Health, Bethesda, MD, USA,
32
INSERM, US14––Orphanet, Plateforme Maladies Rares, 75014 Paris, France, 33 The Jackson Laboratory, Bar
Harbor, ME, USA, 34 Sanford Imagenetics, Sanford Health, Sioux Falls, SD, USA, 35 Center for Undiagnosed
Diseases, Stanford University School of Medicine, Stanford, CA, USA, 36 Department of Genetics, University Medical
Center Utrecht, the Netherlands, 37 Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK,
38
Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA, 39 Mount Sinai School of
Medicine, New York, NY, USA, 40 Institute of Cardiovascular Science, University College London, UK, 41 Child
Neurology Unit. Hospital Universitari Vall d’Hebron, Vall d’Hebron Research Institute (VHIR), Barcelona, Spain,
42
Department of Neuropediatrics and Muscle Disorders, Medical Center––University of Freiburg, Faculty of Medicine,
Freiburg, Germany, 43 Children’s Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa,
Canada, 44 Division of Neurology, Department of Medicine, The Ottawa Hospital, Ottawa, Canada, 45 Centre for Rare
Eye Diseases CARGO, SENSGENE FSMR Network, Strasbourg University Hospital, Strasbourg, France,
46
Immunology Service, Department of Laboratory Medicine, NIH Clinical Center, Bethesda, MD, USA, 47 Department
of Pediatrics, Division of Allergy Immunology, The Children’s Hospital of Philadelphia, University of Pennsylvania
Perelman School of Medicine, 3615 Civic Center Boulevard, Philadelphia, PA 19104, USA and 48 Institute for Systems
Genomics, University of Connecticut, Farmington, CT, USA

D1020 Nucleic Acids Research, 2019, Vol. 47, Database issue

of pathologies or alternatively gene lists created ‘on the
fly’ based on the HPO terms provided with the individual
case. These major databases are not only contributing to
gene discovery and diagnosis of the unsolved patients included in the platforms (10) but also providing source data
for many computational developments. Within the SolveRD project (https://solve-rd.eu), RD-Connect worked with
Orphanet and HPO to implement the first version of the
Phenopackets standard (https://github.com/phenopackets)
and export ∼600 cases in Phenopacket format, including
clinical phenotype (HPO annotation), clinical diagnosis
(ORDO), molecular diagnosis (OMIM) and gene name of
genes identified as causal or candidate. The export included
both solved cases and unsolved cases that contain sufficient
information for phenotypic algorithm evaluation. In addition, work is ongoing that will enable assessment of the correlation between the level, detail and quantity of phenotypic
annotation and the solve rate, which will provide clinicians
with better advice on the level of detail to provide in their
annotations and feed back into improvements to algorithms
such as those implemented in Exomiser.
Ontologies should be responsive to the community (43).
In the past 2 years we have made improvements to the ontology based on input from clinicians and researchers, as
is evidenced by term requests that have been submitted via
our GitHub tracker (12). There, we provide a template that
guides users through the process of providing information
including the suggested term label, definitions and comments, synonyms, references and diseases that should be annotated to the new term. Periodically we also organize collaborative workshops with clinical groups that would like to
revise and extend entire areas of the HPO. Five such workshops have been conducted since the 2017 HPO update (Table 1).
The HPO project additionally has a long-term collaboration with Orphanet in the framework HIPBI-RD (harmonizing phenomics information for a better interoperability
in the rare disease field), a project that was funded by the ERare 3 ERA-NET program (50) and will be continued in the
framework of the SOLVE-RD project, as well as in the European Joint Co-fund Programme for Rare Diseases (EJPRD). This project has resulted in more than 60 000 HPO
annotations for diseases in the Orphanet database and over
one thousand new term requests and other improvements
of existing HPO terms. Phenotype-disease annotations include the frequency of occurrence of a phenotype in a disease (see Table 2), as well as the fact that a phenotype is
part of established diagnostic criteria or is a pathognomonic
sign. These annotations are available for download and can
be consulted in the Orphanet website. Furthermore, this
collaboration has produced the HPO-ORDO Ontological
Module (HOOM in which the HPO and Orphanet Rare
Diseases Ontology can be used together).
LOGICAL ENHANCEMENTS AND INTEROPERABILITY
The HPO provides textual definitions for ease of use, but
it also has a robust logical representation with OWLbased logical definitions based on species-neutral ontologies such as Uberon, the Gene Ontology, the Cell On-
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throughput ascertainment of EHR phenotypes such that
cases and controls of Mendelian diseases could be distinguished and the pathogenicity of variants associated with
Mendelian diseases was characterized (40). In another setting, EHR narratives were explored to extract HPO terms
by natural language processing and the resulting terms were
successfully used to prioritize causal genes for Mendelian
diseases in pediatric patients (41). Additionally, an increasing number of commercial applications are using HPO
terms. For instance, the SimulConsult Genome-Phenome
Analyzer uses HPO terms to tag findings. This is currently
being used to document findings entered by the users with
codes in exported reports, and the codes will also be used
to identify findings in the electronic health record as inputs to be considered in diagnosis (42). A key feature of the
HPO is its logical interoperability with basic research ontologies such as the Mammalian Phenotype Ontology (MP)
(43), Uberon (44) and the Cell Ontology (45). This interoperability is leveraged within the Exomiser tool (described
below). The International Mouse Phenotyping Consortium
(IMPC) recently identified 360 new candidate molecular
causes of human Mendelian diseases (46); these included
an inherited heart disease ‘Arrhythmogenic Right Ventricular Dysplasia’ that affects the heart muscle, and ‘CharcotMarie-Tooth disease’, which is characterized by nerve damage leading to muscle weakness and an awkward way of
walking. This discovery was made possible because (i) the
human diseases had been defined in terms of their component HPO phenotypes; (ii) the mouse phenotypes were
mapped to the MP; and (iii) Monarch’s phenotype comparison algorithm (47) is designed to traverse HP and MP
with ease. Similarly, the Rat Genome Database (RGD) annotates genes, QTLs and strains for phenotype using phenotype terms from the Mammalian Phenotype (MP) Ontology
(43); more recently, RGD has converted their annotations of
human phenotypes from MP to HPO (48).
HPO has been adopted as the phenotypic annotation ontology of choice for many large-scale rare disease genome-phenome databases and analysis tools including the RD-Connect Genome-Phenome Analysis Platform
(GPAP) (49), the Broad Center for Mendelian Genomics
and its SEQR platform, the rare disease arm of the UK
100,000 Genomes Project, the NIH Undiagnosed Diseases
Program and the Undiagnosed Diseases Network International (UDNI). This is creating a vast body of clinically
validated, linked genome-phenome data that not only assists in the diagnosis of the subjects themselves but can
be exploited for further developments of the ontology and
associated diagnostic algorithms. For example, the RDConnect GPAP mandates submission of HPO-coded phenotypic data through the PhenoTips tool, using customdesigned disease-specific data collection forms on top of the
‘enter-what-you-see’ HPO entry box. The average number
of phenotypic annotations per index case is eight (with an
average of six observed and two excluded features) and the
GPAP now contains linked genome-phenome datasets on
5000 individuals. Through data submission from European
Reference Networks in the Horizon 2020-funded Solve-RD
project this number will increase to >20 000 datasets in
the coming 2–3 years. The GPAP allows the user to filter
variants using predefined gene panels for specific groups

Nucleic Acids Research, 2019, Vol. 47, Database issue D1021

Table 1. Community workshops and collaborations aimed at HPO content expansion and refinement
Location

Focus

Undiagnosed Diseases Network (UDN);
Stanford Center for Inherited Cardiovascular
Diseases (SCICD)
European Reference Network for Rare Eye
Disease (ERN-EYE)
National Institute of Allergy and Infectious
Disease (NIAID)
Neuro-MIG European network for brain
malformations (www.neuro-mig.org)
European Society for Immunodeficiencies
(ESID) and the European Reference network
on rare primary immunodeficiency,
autoinflammatory and autoimmune diseases
(ERN-RITA)

Stanford University, CA, USA (March 2017)

Cardiology

Mont Sainte-Odile, France (October 2017)

Ophthalmology

National Institutes of Health, Bethesda, MD,
USA (May and July 2018)
St Julians, Malta; Lisbon, Portugal (February
2018; September 2018)
Vienna Austria (September 2018)

Allergy and immunology
Malformations of cortical development (MCD)
Inborn errors of immunity.

Table 2. The HPO records the frequencies of phenotypic features in three different ways
Frequency categories
Term

ID

Obligate
HP:0040280
Very
HP:0040281
frequent
Frequent
HP:0040282
Occasional
HP:0040283
Very rare
HP:0040284
Excluded
HP:0040285
Percentage of persons in which a phenotypic feature is observed
Percentage
x%

Definition
Always present, i.e. in 100% of the cases.
Present in 80–99% of the cases.
Present in 30–79% of the cases.
Present in 5–29% of the cases.
Present in 1–4% of the cases.
Present in 0% of the cases.

This is used to record frequency of a feature in a disease if the number of probands is
not available, e.g. 42%.
Number of persons in a cohort in whom a phenotypic feature was observed
N of M
n/m
This is used to record how many persons with a certain disease were observed to have a
notation
given phenotypic feature represented by an HPO term, e.g. 5/13. This should be used
only if the feature was ruled out in the remaining m-n individuals.
Frequency information can be used by differential diagnostic algorithms such as BOQA (62). If possible, HPO annotations are made with the precise
counts, but percentages or overall frequency categories are used if that is all that is available. The frequency categories are aligned with those of Orphanet.

tology and others. For instance, Delayed patellar ossification (HP:0006454) is defined with reference to the PATO
term delayed (PATO:0000502), the Gene Ontology term ossification (GO:0001503) and the Uberon term for patella
(UBERON:0002446). The OBO version of the ontology is
a simplified version of the full OWL version that contains
all of the terms as well as their subclass (is-a) relations, but
does not contain the computational logical definitions.
'has part' some
(delayed
and ('inheres in' some
(ossification
and ('occurs in' some patella)))
and ('has modifier' some abnormal))
These logical definitions can be used for quality control (51), to infer new classifications (is a/subclass relationships) that were not explicitly asserted and for cross-species
phenotype analysis (46). However, this can only work if
compatible sets of definitions are used.
Manually maintaining compatible logical definitions
across large ontologies such as the HPO is error-prone and
may lead to inconsistent description in one ontology and
especially across different phenotype ontologies. Even specialized branches of the ontology, such as the ones addressing morphological abnormalities, can have divergent logi-

cal definitions. Pattern-based ontology development practices (52,53) are increasingly used to manage the generation
of logical definitions. Rather than encoding logical definitions manually in OWL using an ontology editor, patternbased development separates the blueprint of the logical definition––essentially the definition with placeholder
variables––from the actual definition of the term, which is
usually encoded in the form of a spreadsheet record. Members of the Monarch Initiative are contributing to community tools for pattern-based development using Dead Simple Ontology Design Patterns (DOSDP, (52)) and the Ontology Development Kit (ODK).
To support the use of model organisms to further human health research, developers of the Mammalian Phenotype (MP) ontology (54) have collaborated with the HPO
team to develop compatible logical definitions, but these efforts were restricted to comparison of individual definitions
and resulted in manual changes to the respective ontologies. Pattern-based development offers a more accurate and
scalable alternative by developing common patterns that
all phenotype ontologies (i.e. all organisms) can refer to
and that can be applied to a whole branch of an ontology
at once. For example, the ‘increasedSize’ pattern defines a
blueprint for a logical definition as follows: “has part’ some
(‘increased size’ and (‘inheres in’ some %s) and (‘qualifier’
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Thirty-six new molecular phenotypes have been added
to the HPO. These new terms were identified from
metabolomics data provided by the Metabolomics Core
from the Undiagnosed Disease Network, the Human
Metabolome Database (HMDB) and articles related to
inborn errors of metabolism. The new terms were curated in a spreadsheet that captured information about
metabolite name, corresponding chemicals and their
identifiers (ChEBI and HMDB), direction of change
(increase/decrease), location of the abnormal metabolite concentration (blood, urine, cerebrospinal fluid),
synonyms, gene/locus association, disease identifiers for
associated diseases (OMIM or MONDO IDs) and key
publication (PubMed IDs). For instance, an increased level
of galactonate in red blood cell (HP:0410063) is associated
with patients with galactosemia (MONDO:0018116; gene:
GALT).
The new Clinical modifier subontology allows more expressive and precise disease definitions and can also be used
to annotate individual patients. This subontology contains
terms to describe severity, positionality and external factors that tend to trigger or ameliorate the features of a disease. The previous Onset subontology has been expanded to
a Clinical course subontology, which additionally contains
terms to describe mortality, progression of disease and the
temporal pattern of features of disease (Figure 1). The frequency of features can be described in one of three methods
(Table 2).
The HPO annotation file format had remained unchanged since the first publication of the HPO in 2008 (57);
to accommodate the aforementioned new annotation resources, we have updated the annotation file format. This
format has slots to capture clinical modifiers, sex-specific
features of disease and to track the history of biocuration
of terms (Table 3).
A new tool called HPOWorkbench has been developed
to enable browsing through HPO terms and annotations.
It can generate GitHub issues directly and can be used by
collaborators to provide feedback or new suggestions.

DISEASE ANNOTATIONS
The HPO project provides a comprehensive set of computable definitions of rare diseases in the form of annotations which describe the clinical features (HPO terms)
that characterize each disease. Each annotated feature can
have metadata including its typical age of onset and the frequency (for instance, the HPO lists the frequency of Protrusio acetabuli [HP:0003179] in persons with Marfan syndrome as 113/146 based on a published clinical study (55)).
Such annotation metadata can be used to improve the accuracy of the HPO-based matching algorithms (56).
Recent updates to our corpus of disease annotations include a new file format with robust representation of clinical modifiers, as well as migration to the Monarch Merged
Disease Ontology (MONDO), which provides a unified set
of disease terms and definitions with computationally declared equivalencies to resources such as OMIM and Orphanet. The annotation data is readily available for computational use via Monarch’s Biolink API (see resources below). We have also produced a new stand-alone tool to aid
curation of the disease annotations.

EXOMISER UPDATE
Exomiser utilizes the HPO to find potential disease-causing
variants from whole-exome or whole-genome sequencing
data. The last two major updates to the Exomiser software
have focused on decoupling the data updates from the software release cycle and enabling analysis of either GRCh37
or GRCh38 genomic samples. We updated the variant data
sources to also include allele frequency data from gnomAD,
TOPMed and the UK10 datasets and added annotations
for variant pathogenicity from ClinVar. We also added the
ability for users to specify fine-grained maximum allele frequencies to be used for prioritizing alleles under different
inheritance models and assigning these to likely syndromes
based on the phenotype matches. Moreover, the Exomiser
variant data sources have not only been decoupled from the
software release cycle, but also from the phenotype ontologies and disease annotations. This ensures that we can release Exomiser with the very latest disease and model organism annotations and that they can be updated on demand.
These user-facing updates have happened against a back-
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some ‘abnormal’))’. Using DOSDP in conjunction with the
ODK, any phenotype ontology developer who needs to define a phenotype describing the increased size of something
(such as an anatomical entity) can now simply commit to
the increasedSize pattern. More than 40 patterns specifically for phenotype ontology development are currently
available in the Uber-Phenotype (UPheno) repository.
The clinical features represented in HPO are connected
via subclass relations. Other relationships between those
classes hold as well, but have not previously been encoded
computationally. For example, phenotype ontologies may
have two separate classes to represent the increase and decrease in size of an anatomical entity such as the liver. To
represent such relations, we have added opposite relations
to all terms in HPO using a text and logic-based approach
(see phenopposites GitHub repository under ‘Availability’).
The Monarch Initiative has been a key organizer of a
community effort to use pattern-based ontology development to reconcile logical definitions on a large scale across
well-established and emerging phenotype ontologies including HPO, MP, and phenotype ontologies for Caenorhabditis
elegans, Xenopus and Drosophila. To that end, we recently
organized a Phenotype Ontology development and reconciliation workshop (Phenotype Ontologies Traversing All
The Organisms: POTATO). At this workshop, more than 40
ontology curators, developers and biomedical experts came
together to learn about our updated tool-chain for patternbased development and to discuss discrepancies between
the logical definitions across various phenotype ontologies.
As a result of the meeting, representatives of all the phenotypes ontologies have committed to an ongoing collaboration to align their respective ontologies by developing
sets of common design patterns and using these to define
terms in their ontologies. The outcome of these community
efforts will be an integrated ecosystem of phenotype ontologies that can be leveraged in HPO-based clinical diagnostics
and disease mechanism discovery.
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A

B
Clinical course
Mortality/Aging
Age of death
...
Onset
Infantile onset
Childhood onset
…
Pace of progression
Nonprogressive
Progressive
…
Temporal pattern
Acute
Nocturnal
…

C

FCAS2
OMIM:611762, MONDO:0012724
familial cold autoinflammatory syndrome 2

has phenotype

f=3/3

Episodic Fever
HP:0001954

modifier

onset

Triggered by cold

Infantile Onset

HP:0025206

HP:0003593

Figure 1. Overview of the clinical modifier (A, left) and clinical course (B, right) subontologies. These subontology terms can be used in combination with
existing HPO terms to qualify and enrich their meaning. (C) A schematic presentation of one HPO annotation for the disease familial cold autoinflammatory syndrome 2 (FCAS2). In a publication on this disease, three of three reported patients were found to have episodic fever with infantile (or earlier)
onset that was triggered by exposure to cold (63).

Table 3. New HPO annotation file format
Field

Item

Required

Example

1
2
3
4
5
6
7
8
9
10
11
12

Database ID
DB Name
Qualifier
HPO ID
DB Reference
Evidence
Onset
Frequency
Sex
Modifier
Aspect
BiocurationBy

Yes
Yes
No
Yes
Yes
Yes
No
No
No
No
Yes
Yes

MIM:154700, ORPHA:558 or MONDO:0007947
Achondrogenesis, type IB
NOT or empty
HP:0002487
OMIM:154700 or PMID:15517394
IEA
HP:0003577
HP:0003577 or 12/45 or 22%
MALE or FEMALE
HP:0025257
‘P’ or ‘C’ or ‘I’ or ‘M’
HPO:skoehler[YYYY-MM-DD]

The file contains 12 tab-separated fields, some of which can be left empty. The ‘Modifier’ and ‘BiocurationBy’ fields can contain multiple items separated
by semicolons. For instance, to indicate that a disease is characterized by a skin rash (HP:0000988) that is Recurrent (HP:0031796) and Triggered by cold
(HP:0025206) one would annotate HP:0031796;HP:0025206 in the Modifier column. Many annotations go through multiple stages of biocuration. In this
case, the individual biocuration events are also added as a semicolon-separated list.
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Clinical modifier
Aggravated by
Aggravated by activity
Exacerbated by head trauma
…
Ameliorated by
Ameliorated by carbohydrate ingestion
Ameliorated by heat
Ameliorated by pregnancy
…
Pain characteristic
Dull
Sharp
…
Position
Laterality
Bilateral
Left
…
Spatial pattern
Acral
Axial
…
Severity
Borderline
Mild
…
Triggered by
Triggered by carbohydrate ingestion
Triggered by cold
...
Refractory
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SYNONYMS AND TRANSLATIONS
One of the key advantages of ontologies is that semantic
meaning is attached to concepts, rather than to their names.
This enables each entity to have one or more synonyms, as
well as translations into other languages. Multiple groups
have taken advantage of this ability to create synonyms for
HPO concepts for diverse settings, including enabling selfphenotyping by patients without medical expertise and enabling capture of data in diverse languages, with subsequent
international sharing and analysis.
Patients themselves are an eager and untapped source
of information about symptoms and phenotypes, however,
medical terminology is often perplexing to them, making
it difficult to use resources like the HPO. Further, some
phenotypes go unnoticed by the clinician (such as those
only seen at home). To enable patients to use the HPO directly and to improve collaboration and communication between patients and their physicians, we have recently added
‘layperson’ synonyms to the entirety of the HPO (58). Approximately 36% of the HPO terms have at least one layperson synonym, 89% of the MONDO diseases annotated to
HPO have at least one HPO annotation with a layperson
synonym and 60% of all disease annotations refer to HPO
terms with lay translations. This coverage suggests that the
layperson HPO would be useful in a diagnostic setting despite incomplete coverage. Efforts are currently underway
to evaluate the diagnostic utility of the layHPO, both synthetically as well as in cohorts of previously diagnosed rare
disease patients.
The Sanford Health Imagenetics program has deployed
an online screening tool for patients to self-report traits,
signs, and symptoms in a questionnaire format that is
mapped to HPO and leverages the layperson synonyms.
This is integrated with the Sanford Imagenetics populationbased genotyping initiative. The Genetic and Rare Diseases Information Center (GARD), a program of the National Center for Advancing Translational Sciences Office
of Rare Diseases Research (NCATS-ORDR), provides reliable, public-friendly information for over 7000 genetic
and/or rare diseases (59). GARD recently incorporated tables on the disease webpages that display information from
the HPO including the medical terms for associated symptoms and phenotypic abnormalities, the related layperson
synonyms, the frequency of the phenotypic features and
the link to the HPO webpage for the specific term. By dis-

playing the plain-language vocabulary along with the medical terminology, patients and families become familiar with
the language they are commonly exposed to in the literature and clinical settings. The public utilizes the HPO medical terms and layperson synonyms to better understand the
broad spectrum of clinical findings associated with a specific disease and to search and navigate the GARD website and other resources to retrieve information about multiple diseases associated with a given phenotype. Inclusion
of the HPO data on the GARD website makes the disease
webpages more robust, educates the rare disease community and empowers them to become partners in their medical care.
The labels, synonyms and textual definitions of the HPO
are also being translated into several languages including French, Spanish, Italian, German, Dutch, Portuguese,
Turkish, Japanese, Russian and Chinese; this is critical to
ensure equitable health care and precision public health (See
project homepage below). Tools such as PhenoTips (60) already make use of the existing Spanish and French translations, together with a user interface in those languages
to enable HPO-based phenotyping for clinicians who are
not fluent in English. In the Spanish Undiagnosed Disease
Network clinicians phenotype patients in Spanish, and then
share with the Matchmaker Exchange (13). One further example is the Life Languages project in Western Australia
(WA), which is using the HPO to translate medical and
biological terms into partner Aboriginal Australian Languages. This is being integrated with HPO term extraction
from 3D facial images as part of the Pilbara Faces program
in remote WA.
NEW HPO WEBSITE
The HPO website application has been redesigned and rebuilt from the ground up to be both more responsive and
more intuitive (Figure 2). Made possible by the new singlepage app approach and lightweight microservices, the new
application loads faster and supports intuitive search capabilities, such as auto-complete and term highlight features,
to allow the user to efficiently browse through the ontology data and corresponding hierarchy. The HPO website
uses the ProtVista tool to display genes and genetic variants associated with Mendelian diseases (61). The redesign
also sets the stage for better integration with monarchinitiative.org to facilitate exploration of similar genes and phenotypes across species.
HPO FOR MEDICAL EDUCATION
Clinical features in HPO are also connected to disease
nosologies (medical classification schemes) such as ORDO,
OMIM, and MONDO. These relationships are typically
curated from literature; however, they can also be crowdsourced. Phenotate (http://phenotate.org), which was developed in the framework of the HIPBI-RD project, is a
web-based tool that allows undergraduate or medical students, as well as medical residents, to annotate OMIM and
ORDO diseases with HPO phenotypes by completing classroom exercises. Students are encouraged to refer to the literature to select the correct symptoms and enter the refer-
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ground of continued engineering and performance improvements. As a result of the continued development and usage,
the Exomiser also recently received the approval of the International Rare Diseases Research Consortium (IRDiRC)
as a recognized resource. We have also been able to build
on HPO being chosen as the terminology for clinical phenotype data collection by the UK National Health Service
(NHS) by introducing Exomiser as a key variant prioritization service for the 100 000 Genomes Project and future
NHS-commissioned service for rare disease genetic testing.
Benchmarking on the solved cases to date shows Exomiser
can identify over 80% of the diagnoses in the top five candidates (unpublished communication from the 100K Genome
project).
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ences used into their annotations. In a second-year undergraduate molecular genetics class (MGY200) at the University of Toronto, 78 students used Phenotate to annotate
three genetic diseases: Marfan syndrome (MFS), Friedreich’s ataxia (FRDA) and congenital myasthenic syndrome.
Overall, students collectively provided more comprehensive annotations than clinicians who also submitted annotations. Phenotate is an open platform, available for use by
anyone teaching genetics. By crowdsourcing annotations,
Phenotate hopes to improve the HPO and related nosologies, while also offering students an educational tool that
supplements their coursework.

CONCLUSION
In the 2 years since the previous Nucleic Acids Research
database article (12), the HPO has continued to grow in
both reach and scope. The HPO has put a strong emphasis
on working with interested members of the community to
revise and extend individual areas of the HPO, and we welcome interactions with more groups in any area of medicine.
The HPO project has begun to develop resources for laypersons to interact with the HPO and software designed for
patients. Annotations and improved representation of phe-

notypes in the HPO have been greatly improved for several
areas of medicine thanks to community interactions.
DATA AVAILABILITY
The Human Phenotype Ontology and its resources are
available at http://www.human-phenotype-ontology.org
Web version of the Exomiser: https://phenomics-dev.kccg.
garvan.org.au/web-exomiser/
Orphanet: http://www.orpha.net
HOOM: HPO-ORDO Ontological Module: http://www.
orphadata.org/
Biolink: https://api.monarchinitiative.org/api/
MONDO: http://obofoundry.org/ontology/mondo.html
Monarch Initiative: https://monarchinitiative.org
Phenotate: http://phenotate.org
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https://github.com/
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Development
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Figure 2. Screenshot of the new HPO Website application. Users can search for HPO terms, annotated diseases, or disease-associated genes using an
autocomplete widget. The hierarchical structure of the ontology is shown in an abbreviated fashion for clarity’s sake. Only the direct parent and child
terms of the currently displayed term are shown in the hierarchy. The total number of decedent terms is shown for each term in the hierarchy to help users
decide which parts of the ontology to explore.
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62. Bauer,S., Köhler,S., Schulz,M.H. and Robinson,P.N. (2012) Bayesian
ontology querying for accurate and noise-tolerant semantic searches.
Bioinformatics, 28, 2502–2508.
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Oddson,A., Másson,G., Holm,H., Kong,A., Thorsteinsdottir,U.,
Sulem,P. et al. (2016) Weighting sequence variants based on their
annotation increases power of whole-genome association studies.
Nat. Genet., 48, 314–317.
40. Bastarache,L., Hughey,J.J., Hebbring,S., Marlo,J., Zhao,W., Ho,W.T.,
Van Driest,S.L., McGregor,T.L., Mosley,J.D., Wells,Q.S. et al. (2018)
Phenotype risk scores identify patients with unrecognized Mendelian
disease patterns. Science, 359, 1233–1239.
41. Son,J.H., Xie,G., Yuan,C., Ena,L., Li,Z., Goldstein,A., Huang,L.,
Wang,L., Shen,F., Liu,H. et al. (2018) Deep phenotyping on
electronic health records facilitates genetic diagnosis by clinical
exomes. Am. J. Hum. Genet., 103, 58–73.
42. Segal,M.M., Rahm,A.K., Hulse,N.C., Wood,G., Williams,J.L.,
Feldman,L., Moore,G.J., Gehrum,D., Yefko,M., Mayernick,S. et al.
(2017) Experience with integrating diagnostic decision support
software with electronic health records: Benefits versus risks of
information sharing. EGEMS, 5, 23.
43. Smith,C.L., Goldsmith,C.-A.W. and Eppig,J.T. (2005) The
Mammalian Phenotype Ontology as a tool for annotating, analyzing
and comparing phenotypic information. Genome Biol., 6, R7.
44. Haendel,M.A., Balhoff,J.P., Bastian,F.B., Blackburn,D.C.,
Blake,J.A., Bradford,Y., Comte,A., Dahdul,W.M., Dececchi,T.A.,
Druzinsky,R.E. et al. (2014) Unification of multi-species vertebrate
anatomy ontologies for comparative biology in Uberon. J. Biomed.
Semantics, 5, 21.
45. Bard,J., Rhee,S.Y. and Ashburner,M. (2005) An ontology for cell
types. Genome Biol., 6, R21.
46. Meehan,T.F., Conte,N., West,D.B., Jacobsen,J.O., Mason,J.,
Warren,J., Chen,C.K., Tudose,I., Relac,M., Matthews,P. et al. (2017)
Disease model discovery from 3,328 gene knockouts by The
International Mouse Phenotyping Consortium. Nat. Genet., 49,
1231–1238.

